Ascendis Pharma struggles after report of Yorvipath patient death

3 hours ago 1

Ascendis Pharma at one point on Monday was down ~12% before closing off just 2.5% after the FDA adverse event report database was updated to reflect the death of an individual taking the hypoparathyroidism drug Yorvipath (palopegteriparatide).
The database entry